BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeng X, Liu L, Zheng M, Sun H, Xiao J, Lu T, Huang G, Chen P, Zhang J, Zhu F, Li H, Duan Q. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget 2016;7:22460-73. [PMID: 26967058 DOI: 10.18632/oncotarget.7984] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Yang X, Wang R, Zhang X. Prognostic Value of PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase (PBK/TOPK) in Patients with Cancer. J Cancer 2019;10:131-7. [PMID: 30662533 DOI: 10.7150/jca.28216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Zhang Y, Li Z, Min Q, Palida A, Zhang Y, Tang R, Chen L, Li H. 8-Chrysoeriol, as a potential BCL-2 inhibitor triggers apoptosis of SW1990 pancreatic cancer cells. Bioorg Chem 2018;77:478-84. [PMID: 29454280 DOI: 10.1016/j.bioorg.2018.01.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
3 Pirovano G, Roberts S, Brand C, Donabedian PL, Mason C, de Souza PD, Higgins GS, Reiner T. [18F]FE-OTS964: a Small Molecule Targeting TOPK for In Vivo PET Imaging in a Glioblastoma Xenograft Model. Mol Imaging Biol 2019;21:705-12. [PMID: 30357568 DOI: 10.1007/s11307-018-1288-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
4 Ma T, Wu M, Jia S, Yang L. Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies. Int J Colorectal Dis 2020;35:2157-69. [DOI: 10.1007/s00384-020-03717-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
6 Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol 2017;80:925-37. [PMID: 28861639 DOI: 10.1007/s00280-017-3426-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
7 Liu M, Tang R, Jiang Y. Pantoprazole Induces Apoptosis of Leukemic Cells by Inhibiting Expression of P-Glycoprotein/Multidrug Resistance-Associated Protein-1 Through PI3K/AKT/mTOR Signaling. Indian J Hematol Blood Transfus 2017;33:500-8. [PMID: 29075060 DOI: 10.1007/s12288-017-0808-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
8 Spugnini E, Fais S. Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering? Semin Cancer Biol 2017;43:111-8. [PMID: 28088584 DOI: 10.1016/j.semcancer.2017.01.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
9 Xiao J, Wang F, Lu H, Xu S, Zou L, Tian Q, Fu Y, Lin X, Liu L, Yuan P, Ni X, Ma T, Zeng F, Xue P, Xiu R, Zhang J, Ji X, Hu H, Lu S, Dai H, Li Y, Chu Q, Zhao X, Duan Q, Zhu F. Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells. Cell Death Dis 2019;10:777. [PMID: 31611604 DOI: 10.1038/s41419-019-2020-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
10 Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018;33:614-624. [PMID: 30071147 DOI: 10.1002/ncp.10181] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
11 Li Z, Zhang Y, Chen L, Li H. The dietary compound luteolin inhibits pancreatic cancer growth by targeting BCL-2. Food Funct 2018;9:3018-27. [DOI: 10.1039/c8fo00033f] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
12 Hu QF, Gao TT, Shi YJ, Lei Q, Liu ZH, Feng Q, Chen ZJ, Yu LT. Design, synthesis and biological evaluation of novel 1-phenyl phenanthridin-6(5H)-one derivatives as anti-tumor agents targeting TOPK. Eur J Med Chem 2019;162:407-22. [PMID: 30453248 DOI: 10.1016/j.ejmech.2018.11.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lu ZN, Shi ZY, Dang YF, Cheng YN, Guan YH, Hao ZJ, Tian B, He HW, Guo XL. Pantoprazole pretreatment elevates sensitivity to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo. Biomed Pharmacother 2019;120:109478. [PMID: 31568987 DOI: 10.1016/j.biopha.2019.109478] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
14 Zhang C, Tan X, Feng J, Ding N, Li Y, Jin Z, Meng Q, Liu X, Hu C. Design, Synthesis and Biological Evaluation of a New Series of 1-Aryl-3-{4-[(pyridin-2-ylmethyl)thio]phenyl}urea Derivatives as Antiproliferative Agents. Molecules 2019;24:E2108. [PMID: 31167363 DOI: 10.3390/molecules24112108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Quan C, Xiao J, Duan Q, Yuan P, Xue P, Lu H, Yan M, Guo D, Xu S, Zhang X, Lin X, Wang Y, Dogan S, Zhang J, Zhu F, Ke C, Liu L. T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma. Oncotarget 2018;9:7782-95. [PMID: 29487691 DOI: 10.18632/oncotarget.23674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
16 Sasaki T, Mori S, Kishi S, Fujiwara-Tani R, Ohmori H, Nishiguchi Y, Hojo Y, Kawahara I, Nakashima C, Fujii K, Luo Y, Kuniyasu H. Effect of Proton Pump Inhibitors on Colorectal Cancer. Int J Mol Sci 2020;21:E3877. [PMID: 32485921 DOI: 10.3390/ijms21113877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Huang H, Lee MH, Liu K, Dong Z, Ryoo Z, Kim MO. PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential. Cancers (Basel) 2021;13:2232. [PMID: 34066486 DOI: 10.3390/cancers13092232] [Reference Citation Analysis]
18 Guo D, Wang C, Wang Q, Qiao Z, Tang H. Pantoprazole blocks the JAK2/STAT3 pathway to alleviate skeletal muscle wasting in cancer cachexia by inhibiting inflammatory response. Oncotarget. 2017;8:39640-39648. [PMID: 28489606 DOI: 10.18632/oncotarget.17387] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
19 Zhao R, Huang H, Choi BY, Liu X, Zhang M, Zhou S, Song M, Yin F, Chen H, Shim J, Bode AM, Dong Z, Lee M. Cell growth inhibition by 3-deoxysappanchalcone is mediated by directly targeting the TOPK signaling pathway in colon cancer. Phytomedicine 2019;61:152813. [DOI: 10.1016/j.phymed.2018.12.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
20 Wong GG, Ha V, Chu MP, Dersch-Mills D, Ghosh S, Chambers CR, Sawyer MB. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. Clin Colorectal Cancer 2019;18:72-9. [PMID: 30551953 DOI: 10.1016/j.clcc.2018.11.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
21 Chen CH, Lee CZ, Lin YC, Kao LT, Lin HC. Negative Association of Proton Pump Inhibitors With Subsequent Development of Breast Cancer: A Nationwide Population-Based Study. J Clin Pharmacol 2019;59:350-5. [PMID: 30329162 DOI: 10.1002/jcph.1329] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
22 Kim SY, Lee JS, Kang J, Morita S, Park YS, Sakamoto J, Muro K, Xu RH, Kim TW. Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). Oncologist 2021;26:e954-62. [PMID: 33644953 DOI: 10.1002/onco.13735] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Zhang L, Wang F, Yi H, Ermakova SP, Malyarenko OS, Mo J, Huang Y, Duan Q, Xiao J, Zhu F. The role of T-LAK cell-originated protein kinase in targeted cancer therapy. Mol Cell Biochem 2022. [PMID: 35037144 DOI: 10.1007/s11010-021-04329-5] [Reference Citation Analysis]
24 Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ. Potential proton pump inhibitor-related adverse effects. Ann N Y Acad Sci 2020;1481:43-58. [PMID: 32761834 DOI: 10.1111/nyas.14428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
25 Turanli B, Altay O, Borén J, Turkez H, Nielsen J, Uhlen M, Arga KY, Mardinoglu A. Systems biology based drug repositioning for development of cancer therapy. Semin Cancer Biol 2021;68:47-58. [PMID: 31568815 DOI: 10.1016/j.semcancer.2019.09.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
26 Zheng M, Luan S, Gao S, Cheng L, Hao B, Li J, Chen Y, Hou X, Chen L, Li H. Proton pump inhibitor ilaprazole suppresses cancer growth by targeting T-cell-originated protein kinase. Oncotarget 2017;8:39143-53. [PMID: 28388576 DOI: 10.18632/oncotarget.16609] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
27 Pirovano G, Roberts S, Reiner T. TOPKi-NBD: a fluorescent small molecule for tumor imaging. Eur J Nucl Med Mol Imaging 2020;47:1003-10. [PMID: 31734783 DOI: 10.1007/s00259-019-04608-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zykova TA, Zhu F, Wang L, Li H, Bai R, Lim DY, Yao K, Bode AM, Dong Z. The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis. EBioMedicine 2017;18:73-82. [PMID: 28412249 DOI: 10.1016/j.ebiom.2017.04.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
29 Ihraiz WG, Ahram M, Bardaweel SK. Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells. Acta Pharmaceutica 2020;70:179-90. [DOI: 10.2478/acph-2020-0020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
30 Wang L, Zhang Z, Ge R, Zhang J, Liu W, Mou K, Lv S, Mu X. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase. Anticancer Agents Med Chem 2019;19:1029-36. [PMID: 30827262 DOI: 10.2174/1871520619666190301123131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Zheng M, Sun W, Gao S, Luan S, Li D, Chen R, Zhang Q, Chen L, Huang J, Li H. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1. Oncotarget 2017;8:44255-65. [PMID: 28498812 DOI: 10.18632/oncotarget.17464] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
32 Nassar H, Abu-dahab R, Taha M. Inhibition of protein kinases by proton pump inhibitors: computational screening and in vitro evaluation. Med Chem Res 2021;30:2266-76. [DOI: 10.1007/s00044-021-02812-8] [Reference Citation Analysis]
33 Lei WY, Wang JH, Yi CH, Liu TT, Hung JS, Wong MW, Bair MJ, Vaezi MF, Orr WC, Chen CL. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clin Res Hepatol Gastroenterol 2021;45:101397. [PMID: 32224118 DOI: 10.1016/j.clinre.2020.02.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]